Study to Assess the Occurrence of HPA-1a Alloimmunization in Women With Higher Risk for Fetal and Neonatal Alloimmune Thrombocytopenia

Active, not recruitingOBSERVATIONAL
Enrollment

30,000

Participants

Timeline

Start Date

March 14, 2022

Primary Completion Date

January 31, 2025

Study Completion Date

October 31, 2025

Conditions
Fetal and Neonatal Alloimmune Thrombocytopenia
Interventions
OTHER

Clinical data collection

Laboratory tests, Vital assessments, Maternal and fetal genotype testing, Antibodies Testing will be performed.

Trial Locations (28)

10029

Icahn School of Medicine at Mount Sinai, New York

10032

Columbia University Irving Medical Center, New York

10065

New York-Presbyterian-Queens, New York

Weill Cornell Medicine-New York Presbyterian Hospital, New York

19140

Temple Perinatal Diagnosis Center, Philadelphia

27599

University of North Carolina at Chapel Hill, Chapel Hill

33136

University of Miami Miller School of Medicine, Miami

43210

Ohio State University Wexner Medical Center, Columbus

45409

Wright State Physicians Obstetrics & Gynecology, Dayton

75230

Javara Inc. - Forest, Dallas

77030

The University of Texas Health Science Center at Houston, Houston

77054

Javara Research Inc. - Dallas - PPDS, Houston

85224

New Horizons Clinical Trials, LLC, Chandler

90247

Zillan Clinical Research - Gardena, Gardena

06511

Yale University School of Medicine, New Haven

08103

Cooper University Hospital, Camden

08901

Robert Wood Johnson Medical School, New Brunswick

St. Peter's University Hospital, New Brunswick

07103

Rutgers New Jersey Medical School, Newark

M4N 3M5

Sunnybrook Health Sciences Centre, Toronto

07747

Klinikum der Friedrich Schiller Universität Jena, Jena

2333 ZA

Leids Universitair Medisch Centrum, Leiden

0524

Oslo Universitetssykehus HF, Ullevål, Oslo

NO-9019

Universitetssykehuset Nord Norge, Tromsø

222 42

Barnmorskestationen Rosengård, Lund

118 83

Södersjukhuset, Stockholm

752 37

Clinical Trial Consultants - Uppsala, Uppsala

SE1 7EH

St. Thomas' Hospital, London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Rallybio

INDUSTRY

NCT05345561 - Study to Assess the Occurrence of HPA-1a Alloimmunization in Women With Higher Risk for Fetal and Neonatal Alloimmune Thrombocytopenia | Biotech Hunter | Biotech Hunter